NCT06296953View on ClinicalTrials.gov

Safety & Feasibility of PERIsign System in Demonstrating Involuntary Muscle Defense as a Sign of Peritonitis in Subjects With Appendicitis

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2024

Conditions
Appendicitis AcuteAppendicitisAbdominal PainPeritonitis
Interventions
DEVICE

PERIsign examination

Patients will be examined with the new device, PERIsign

Trial Locations (2)

Unknown

Hallands Sjukhus Halmstad, Halmstad

Hallands Sjukhus Varberg, Varberg

Sponsors

Collaborators (1)

Aurevia
All Listed Sponsors
collaborator

Aurevia

INDUSTRY

collaborator

Region Halland

OTHER

lead

STB INN AB

INDUSTRY

NCT06296953 - Safety & Feasibility of PERIsign System in Demonstrating Involuntary Muscle Defense as a Sign of Peritonitis in Subjects With Appendicitis | Biotech Hunter | Biotech Hunter